Drug intelligence / Profile preview

Compound Tinglizi

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

Compound Tinglizi is a formulation used in Traditional Chinese Medicine, primarily containing Lepidium seed (葶苈子) as its main ingredient. It is used to treat conditions like pulmonary heart disease and heart failure. The formulation is designed to enhance the therapeutic effects of Lepidium seed, which is known for its properties in draining excess water and phlegm from the lungs, thus alleviating symptoms such as wheezing and edema.

Other names: 复方葶苈子胶囊

Targets

IL-6 (Interleukin 6)TP53 (Cellular Tumor Antigen p53 R175H)HMOX1 (Heme oxygenase 1)

Beyond the preview

Go deeper on Compound Tinglizi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Compound Tinglizi.

Explore the full profile